Clinical trials: Liver Tumour
Melanoma, Non-small Cell Lung Carcinoma (NSCLC)
LITT and Pembrolizumab in Recurrent Brain Metastasis
This is an open-label, historically controlled pilot study investigating the immune effect of Laser Interstitial ThermotHerapy (LITT)+ pembrolizumab in adult patients with a primary cancer approved by the FDA for treatment with…
- Conditions
- Melanoma, Non-small Cell Lung Carcinoma (NSCLC), Renal Cell Carcinoma (RCC), Small-cell Lung Cancer
- Trial name
- TORCH (NCT04187872)
- Testing
- LITT + Pembrolizumab
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- University of Florida
Hilar Cholangiocarcinoma, Primary Sclerosing Cholangitis
Liver Transplantation for Hilar Cholangiocarcinoma in Association With Neoadjuvant Radio- and Chemo-therapy
Single-arm pilot clinical trial. Patients with non operable CC associated with PSC will be subjected to liver transplantation after a neoadjuvant multimodal therapy protocol.
- Trial name
- NCT01549795
- Testing
- Liver transplantation, 45 Gy external radiations, Endoluminal bile duct Brachytherapy
- Where
- Italy
- Volunteers
- 33 people
- Sponsor
- Azienda Ospedaliera di Padova
Cancer, Injury of Liver
Implementing Online Patient-Provider Communication Into Clinical Practice
This interdisciplinary, international collaboration study, including the the Norwegian Health Economy Administration (HELFO) will evaluate the effectiveness and real-world implementation of an online patient-provider…
- Conditions
- Cancer, Injury of Liver, Diabetes
- Trial name
- OPPC (NCT00971139)
- Testing
- Access to an OPPC service
- Where
- Norway
- Volunteers
- 199 people
- Sponsor
- Oslo University Hospital
Circulating Tumor Cell;, Hepatocellular Carcinoma
Decrease in Circulating Tumour Cell Count Reflects the Effectiveness of Postoperative Adjuvant Transarterial Chemoembolization (TACE) in Preventing Hepatocellular Carcinoma Recurrence
Circulating tumour cell (CTC) count could reflect the effect of postoperative transarterial chemoembolization (TACE) on hepatocellular carcinoma (HCC) recurrence.
- Trial name
- NCT02032368
- Testing
- transarterial chemoembolization (TACE)
- Where
- China
- Volunteers
- 57 people
- Sponsor
- Guangdong Provincial People's Hospital
Hepatic Carcinoma
A Clinical Study in Patients With High-risk Recurrent Primary Hepatocellular Carcinoma Using Autologous TILs
Early clinical trials on evaluating the tolerance, safety and efficacy of autologous TILs in high-risk recurrent primary hepatocellular carcinoma
- Trial name
- NCT04538313
- Testing
- Tumor infiltrating lymphocyte
- Where
- China
- Volunteers
- 40 people
- Sponsor
- CAR-T (Shanghai) Cell Biotechnology Co., Ltd.
Colorectal Cancer, Liver Metastases
ctDNA-guided Adjuvant Chemotherapy in Liver Metastasis of Colorectal Cancer
The goal of this clinical trial is to compare in resectable colorectal cancer liver metastasis patients.The main question it aims to answer is whether the 3-year progression-free survival rate (PFS) of "watching and waiting" is…
- Conditions
- Colorectal Cancer, Liver Metastases, Circulating Tumor Cell, Chemotherapy Effect
- Trial name
- NCT05815082
- Testing
- Colorectal cancer resection combined with liver metastasis resection., FOLFOX chemotherapy regimen
- Where
- China
- Volunteers
- 490 people
- Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
Carcinoma, Hepatocellular
Proton Radiotherapy Versus Radiofrequency Ablation for Patients With Medium or Large Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) is one of the most common cancers in Taiwan, where chronic viral hepatitis is common. Patients with HCC typically have impaired liver function because of virus- or alcohol- induced cirrhosis and…
- Trial name
- NCT02640924
- Testing
- Proton radiotherapy, Radiofrequency Ablation
- Where
- Taiwan
- Volunteers
- 166 people
- Sponsor
- Chang Gung Memorial Hospital
Hepatocellular Carcinoma (HCC)
A Study to Compare the Efficacy, Safety, Immunogenicity, and Pharmacokinetic Profile of HLX13 with YERVOY As a First-Line Treatment for Patients with Unresectable Hepatocellular Carcinoma
This is a multicenter, randomized, double-blind, parallel-controlled integrated phase I/III clinical study to evaluate the efficacy, safety, PK, and immunogenicity of HLX13 and YERVOY® in patients with unresectable hepatocellular…
- Trial name
- NCT06841185
- Testing
- HLX13, US-sourced YERVOY®, EU-sourced YERVOY®
- Volunteers
- 656 people
- Sponsor
- Shanghai Henlius Biotech
Hepatocellular Carcinoma, Regorafenib
Regorafenib Combined With PD-1 Inhibitor Therapy for Second-line Treatment of Hepatocellular Carcinoma
This is a single arm, nonrandomized, single center clinical study to investigate the safety and efficacy of regorafenib combined with PD-1 inhibitor therapy for second-line treatment of hepatocellular carcinoma
- Conditions
- Hepatocellular Carcinoma, Regorafenib, PD-1 Inhibitor
- Trial name
- NCT05048017
- Testing
- Regorafenib, PD-1 inhibitor
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Peking Union Medical College Hospital
Hepatocellular Carcinoma (HCC)
Comparison of SBRT and SIRT With Combination IO for Locally-advanced, Unresectable HCCs (BIIRTH)
The goal of this clinical trial is to compare the safety and efficacy of sequential Transarterial Chemoembolization (TACE) and Stereotactic body radiation therapy (SBRT) versus Y90-radioembolisation (SIRT), followed by systemic…
- Trial name
- BIIRTH (NCT07293468)
- Testing
- Transarterial chemoembolization (TACE), Stereotactic Body Radiation Therapy (SBRT), SIRT Yttrium-90
- Where
- Hong Kong
- Volunteers
- 106 people
- Sponsor
- Tuen Mun Hospital
Hepatocellular Carcinoma
Association of Conformational High-dose Radiotherapy and of Hyperselective Transarterial Chemoembolization in the Treatment of Hepatocellular Carcinoma
Indication : Hepatocellular carcinoma, maximum size 9 cm, with single or multiple nodes whose total tumor mass can technically be irradiated, non-resectable, and not a candidate for percutaneous therapy with recommended treatment…
- Trial name
- TACERTE (NCT01300143)
- Testing
- TACE, TACE+ RTC
- Where
- 18 sites in France
- Volunteers
- 126 people
- Sponsor
- Nantes University Hospital
Hepatocellular Carcinoma
Interest of the Intervention of a Nurse Coordinator in Complex Care Pathway
This project is based on the assumption that the nurse coordinators of the centres have common missions at each of the key stages of patient care.
- Trial name
- INFIC (NCT04209491)
- Where
- France
- Volunteers
- 1,000 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Hepatocellular Carcinoma
Phase I/II Study of OPB-31121 in Patients With Progressive Hepatocellular Carcinoma
The purpose of this study is: Phase1: To evaluate the safety and determine the recommended dose (RD) Phase2: To evaluate the efficacy
- Trial name
- NCT01406574
- Testing
- OPB-31121, OPB-31121 phase2
- Where
- 2 sites in Japan
- Volunteers
- 23 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Advanced Hepatocellular Carcinoma
A Study of TAE+HAIC Combined With Camrelizumab and Apatinib in the Treatment of Advanced Hepatocellular Carcinoma
To evaluate the efficacy and safety of TAE+HAIC combined with camrelizumab and apatinib in the treatment of advanced liver cancer with high tumor load
- Trial name
- NCT06363825
- Testing
- camrelizumab
- Where
- China
- Volunteers
- 57 people
- Sponsor
- Fujian Medical University
Liver Cancer
Sorafenib Tosylate Before and After Hepatic Arterial Chemoembolization With Doxorubicin Hydrochloride and Mitomycin C in Treating Patients With Localized Liver Cancer That Cannot Be Removed by Surgery
RATIONALE: Sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00949182
- Testing
- sorafenib tosylate, HACE : Doxorubicin Hydrochloride and Mitomycin C, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Rutgers, The State University of New Jersey
All Cause Mortality, Cardiovascular Diseases
Advice of Moderate Drinking Pattern Versus Advice on Abstention on Major Disease and Mortality
The goal of this clinical trial is to test two advices on alcohol drinking in more than 10.000 Spanish adult drinkers (men of 50 or more years and women of 55 or more years).
- Conditions
- All Cause Mortality, Cardiovascular Diseases, Invasive Cancer, Liver Cirrhosis
- Trial name
- UNATI (NCT06338215)
- Testing
- Moderate Alcohol Drinking Pattern, Abstention
- Where
- Spain
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Clinica Universidad de Navarra, Universidad de Navarra
Pancreatic Cancer, Pancreas Cancer
Daily Online Adaptation Versus Localization for MRI-Guided SBRT for Unresectable Primary or Oligometastatic Abdominal Malignancies
In light of this new technology and preliminary findings of low toxicity of online, adaptive, magnetic resonance (M)-guided stereotactic radiation on a single arm prospective study, the investigators propose to compare this…
- Conditions
- Pancreatic Cancer, Pancreas Cancer, Cancer of the Pancreas, Hepatocellular Carcinoma
- Trial name
- NCT02950025
- Testing
- Online, adaptive MR-guided SBRT, Online, non-adaptive MR-guided SBRT, European Organization for Research and Treatment of Cancer (EORTC) QLQ-30
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Washington University School of Medicine
Hepatitis B, Lymphoma
Tenofovir to Prevent HBV Reactivation
The purpose of the study is to determine how effective preemptive tenofovir therapy is in preventing the re-activation of Hepatitis B infection, in patients who are receiving rituximab-based chemotherapy for Non-Hodgkin's…
- Conditions
- Hepatitis B, Lymphoma, Non-Hodgkin
- Trial name
- NCT02186574
- Testing
- Tenofovir disoproxil
- Where
- 2 sites in Canada
- Volunteers
- 184 people
- Sponsor
- University Health Network, Toronto
Hepatocellular Carcinoma
A Phase 1-2 Study of CF102 in Patients With Advanced Hepatocellular Carcinoma
This trial will test the safety and efficacy of CF102 in patients with advanced liver cancer. Successive groups of patients will be given higher doses of CF102 by mouth on a twice-daily basis.
- Trial name
- NCT00790218
- Testing
- CF102
- Where
- Israel
- Volunteers
- 19 people
- Sponsor
- Can-Fite BioPharma
Hepatoblastoma, Hepatic Hemangioendothelioma
Deep Learning Magnetic Resonance Imaging Radiomics for Diagnostic Value of Hepatic Tumors in Infants
Hepatic tumors in the perinatal period are associated with significant morbidity and mortality in affected patients. The conventional diagnostic tool, such as alpha-fetoprotein (AFP) shows limited value in diagnosis of infantile…
- Trial name
- NCT05170282
- Testing
- Radiomic Algorithm
- Where
- China
- Volunteers
- 200 people
- Sponsor
- West China Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.